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drugs, including a diuretic). A subset of patients (n129) is being followed to 3 years
post-RDN (35 consented to laboratory assessments to 3 years). The primary endpoint is
change in office-based BP from baseline. Data collection includes office-based BP
measurement every 6 months, renal function, electrolytes, and medication usage.
Results: A total of 34 patients have reached the 3 year follow-up time point (9 with labs).
Baseline BP was 175/9812/11 mmHg. Mean SBP change post-RDN was -18.016.6
mm Hg at 1 month, -28.4 17.6 mm Hg at 6 months, -27.6 16.3 mm Hg at 2 years
and -31.3 14.9 mm Hg at 3 years. Medication usage remained similar to baseline with
35% aldosterone antagonist, 85% beta blocker and 82% calcium channel blocker use at
baseline and at 3 years; diuretic use 91% and 88%, angiotensin receptor antagonists 71% and
76%, and ACE inhibitors 50% and 59% at baseline and 3 years, respectively. At 3 years
estimated glomerular filtration rates (eGFR) declined by -13.212.1 from a baseline of
82.216.1 mL/min/m2.
Conclusions: Among patients with full 3 year follow-up, RDN results in significant,
sustained lowering of SBP in patients with treatment-resistant hypertension and a baseline
SBP 160 mm Hg. Antihypertensive medication usage was similar at baseline and 3 years.
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Aims: To evaluate the clinical safety and effectiveness of the DESolve™ Myolimus-
Eluting Bioresorbable Coronary Scaffold (BCSS)in patients with single de novo native
coronary artery lesions through clinical endpoints and multiple imaging modalities.
Methods and Results: Background: The DESolve BCSS is a novel drug eluting device
that combines a PLLA-based scaffold coated with a bioresorbable polylactide-based
polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor has
demonstrated potent anti-proliferative properties in two First-in-Man (FIM) trials using
Elixir’s metallic Myolimus-eluting coronary stents. Drug dose is 3 mcg per mm of scaffold
length; the same dose used in the FIM studies. Sixteen patients with single, de novo
coronary artery lesions were enrolled in this prospective, multi-center, single-arm FIM
study. One patient did not receive a study stent and was deregistered. The 15 remaining
patients are being analysed for multiple clinical endpoints: Device and Procedure Success;
Major Adverse Cardiac Events (MACE), a composite endpoint of cardiac death, target
vessel MI, and clinically-indicated target lesion revascularization (CI-TLR); clinically-
indicated Target Lesion and Target Vessel Revascularization, (CI-TVR) and stent
thrombosis assessed at 1, 6 and 12 months and annually to 5 years. Multiple assessments
by angiographic, IVUS and OCT at 6 months were completed. An additional analysis
using multislice computed tomography (MSCT) will be completed at 12 and 24 months.
At 6 months, the in-scaffold late lumen loss was 0.19  0.19 by QCA, the % volume
obstruction was 7.18  3.37 by IVUS, and by OCT 98.68  2.44% of struts were
demonstrated as covered. There was one MACE event, a TLR, during the follow-up
period. Detailed clinical and imaging results through 12 months will be presented.
Conclusion: The DESolve™ Myolimus-Eluting BCSS demonstrated both excellent
safety and effectiveness in this FIM study, thus warranting further clinical evaluation of the
novel technology in larger clinical studies. Detailed clinical and imaging results through 12
months will be presented.
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Background: The reasons for switching from prasugrel back to clopidogrel after
percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) are
unclear, but are frequently practiced. The study aims to compare the characteristics and
in-hospital outcomes of patients initially given prasugrel but was switched back to
clopidogrel versus those who were continued on prasugrel on discharge.
Methods: The study included a cohort of 152 consecutive AMI patients who were first
loaded with prasugrel and underwent PCI. Patients were categorized into switched
therapy to clopidogrel on discharge (Switched, n58) and continued therapy on prasugrel
on discharge (Continued, n94). Patient and procedural characteristics, as well as
PCI-related complications and in-hospital outcomes were evaluated.
Results: Baseline demographics and procedural characteristics of both groups were
similar. Patients who switched to clopidogrel on discharge had significantly longer
hospital stay, and intensive care unit stay trended longer. Switched patients had
significantly higher incidence of blood transfusions. Major bleeding, hematocrit drop,
hematoma and urgent coronary artery bypass grafting (CABG) also trended higher in
patients who switched therapy.
Concomitant coumadin therapy was significantly higher in the switched therapy group,
whereas aspirin therapy was similar in both groups. No in-hospital mortality or myocardial
infarction occurred in either groups (Table).
Conclusion: In-hospital bleeding complications requiring blood transfusion, need for
urgent CABG and concomitant coumadin therapy are the main reasons for switching of
antiplatelet therapy from prasugrel to clopidogrel prior to discharge.
In-hospital outcomes and concomitant therapy on discharge
Switched to
clopidogrel
(n58)
Continued on
prasugrel
(n94) P value
Length of stay in intensive
care unit (days)
1.1 1.5 0.7 1.0 0.051
Overall hospital length of
stay (days)
4.3 4.3 2.9 1.8 0.021
Death or Q wave
myocardial infarction
0 0 -
Coronary artery bypass
grafting
3 (5.2%) 0 0.054
Blood transfusion 7 (12.1%) 0 0.001
Major bleeding 4 (6.9%) 1 (1.1%) 0.070
Hematocrit drop 15% 5 (8.5%) 1 (1.1%) 0.060
Hematoma 4 (6.9%) 1 (1.1%) 0.070
Concomitant coumadin
therapy on discharge
10 (17.2%) 5 (5.3%) 0.017
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Background: Thrombin injection has been the treatment of choice for iatrogenic arterial
pseudoaneurysms (PSAs). However, certain morphological features of the PSA, i.e. neck
width and length, occasionally precludes the use of this treatment option using the current
recommended technique.
Methods: Between March 2008 and June 2012, 146 consecutive patients who underwent
thrombin injection for post percutaneous coronary intervention related PSAs were
retrospectively studied. The technique of injecting as superficial and as far from the PSA
tract is compared with injecting at the ‘neck’ of the PSA.
Results (Table) Ninety-one patients had superficial thrombin injection (STI) and 55
patients had neck thrombin injection (NTI). Baseline characteristics were similar in both
groups. At the time of injection, all patients were on dual antiplatelet therapy and 9.6%
were on oral anti-coagulation therapy without significant difference between both groups.
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